AstraZeneca (AZN) Receives “Buy” Rating from Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities research analysts at Shore Capital in a research note issued to investors on Thursday.

A number of other equities analysts have also commented on the stock. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research report on Tuesday, January 1st. JPMorgan Chase & Co. set a GBX 6,900 ($90.16) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, January 1st. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Monday, January 21st. Societe Generale lifted their price objective on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the company a “buy” rating in a report on Wednesday, January 16th. Finally, HSBC set a GBX 4,860 ($63.50) price objective on shares of AstraZeneca and gave the company a “sell” rating in a report on Wednesday, November 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of GBX 6,243.45 ($81.58).

Shares of LON:AZN opened at GBX 6,012 ($78.56) on Thursday. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: How to execute a trade ex-dividend strategy?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply